p.84 抽出テキスト
CLINICAL STATEMENTS AND GUIDELINES August 29, 2023 Circulation. 2023;148:e9–e119. DOI: 10.1161/CIR.0000000000001168 Virani et al 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med. 2011;171:134–140. 17. Fernandes N, Prada L, Rosa MM, et al. The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis. Clin Res Cardiol. 2021;110:183– 193. 18. Sara JD, Prasad M, Eleid MF, et al. Association between work-related stress and coronary heart disease: a review of prospective studies through the job strain, effort-reward balance, and organizational justice models. J Am Heart Assoc. 2018;7:e008073. 19. Brewer LC, Redmond N, Slusser JP, et al. Stress and achievement of cardiovascular health metrics: the American Heart Association Life's Simple 7 in blacks of the Jackson Heart Study. J Am Heart Assoc. 2018;7:e008855. 20. Jiao Z, Kakoulides SV, Moscona J, et al. Effect of Hurricane Katrina on incidence of acute myocardial infarction in New Orleans three years after the storm. Am J Cardiol. 2012;109:502–505. 21. Ayotte BJ, Hausmann LR, Whittle J, et al. The relationship between perceived discrimination and coronary artery obstruction. Am Heart J. 2012;163:677–683. 22. Langford AT, Butler M, Booth JN, et al. Stress and depression are associated with life's simple 7 among African Americans with hypertension: findings from the Jackson Heart Study. Am J Hypertens. 2021;34:1311–1321. 23. Le J, Dorstyn DS, Mpofu E, et al. Health-related quality of life in coronary heart disease: a systematic review and meta-analysis mapped against the International Classification of Functioning, Disability and Health. Qual Life Res. 2018;27:2491–2503. 24. Wellenius GA, Mukamal KJ, Kulshreshtha A, et al. Depressive symptoms and the risk of atherosclerotic progression among patients with coronary artery bypass grafts. Circulation. 2008;117:2313–2319. 25. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66:802–813. 26. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014;129:1350–1369. 27. Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, and cardiovascular disease. Am J Hypertens. 2015;28:1295– 1302. 28. Jiang W, Velazquez EJ, Kuchibhatla M, et al. Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA. 2013;309:2139–2149. 29. Celano CM, Millstein RA, Bedoya CA, et al. Association between anxiety and mortality in patients with coronary artery disease: a meta-analysis. Am Heart J. 2015;170:1105–1115. 30. Arnold SV, Smolderen KG, Buchanan DM, et al. Perceived stress in myocardial infarction: long-term mortality and health status outcomes. J Am Coll Cardiol. 2012;60:1756–1763. 31. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41:1284–1292. 32. Plummer F, Manea L, Trepel D, et al. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24–31. 33. Hasnain M, Vieweg WVR, Lesnefsky EJ, et al. Depression screening in patients with coronary heart disease: a critical evaluation of the AHA guidelines. J Psychosom Res. 2011;71:6–12. 34. Ladwig S, Zhou Z, Xu Y, et al. Comparison of treatment rates of depression after stroke versus myocardial infarction: a systematic review and metaanalysis of observational data. Psychosom Med. 2018;80:754–763. 35. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289:3106–3116. 36. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701–709. 37. van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry. 2007;190:460–466. 38. Doyle F, Freedland KE, Carney RM, et al. Hybrid systematic review and network meta-analysis of randomized controlled trials of interventions for depressive symptoms in patients with coronary artery disease. Psychsom Med. 2021;83:423–431. 39. Rutledge T, Redwine LS, Linke SE, et al. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med. 2013;75:335–349. 40. Blumenthal JA, Sherwood A, Smith PJ, et al. Enhancing cardiac rehabilita- tion with stress management training: a randomized, clinical efficacy trial. Circulation. 2016;133:1341–1350. 41. Scott-Sheldon LAJ, Gathright EC, Donahue ML, et al. Mindfulness-based interventions for adults with cardiovascular disease: a systematic review and meta-analysis. Ann Behav Med. 2020;54:67–73. 42. Nijjar PS, Connett JE, Lindquist R, et al. Randomized trial of mindfulnessbased stress reduction in cardiac patients eligible for cardiac rehabilitation. Sci Rep. 2019;9:18415. 43. Ski CF, Jelinek M, Jackson AC, et al. Psychosocial interventions for patients with coronary heart disease and depression: a systematic review and metaanalysis. Eur J Cardiovasc Nurs. 2016;15:305–316. 44. Zhang Y, Liang Y, Huang H, et al. Systematic review and meta-analysis of psychological intervention on patients with coronary heart disease. Ann Palliat Med. 2021;10:8848–8857. 45. Ostuzzi G, Turrini G, Gastaldon C, et al. Efficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysis. Int Clin Psychopharmacol. 2019;34:65–75. 46. Levine GN. The mind-heart-body connection. Circulation. 2019;140:1363– 1365 4.2.3. Tobacco Products 1. US Department of Health and Human Services. Tobacco Use and Depen- dence Guideline Panel Treating Tobacco Use and Dependence: 2008 Update. US Department of Health and Human Services; 2008. 2. Babb S, Malarcher A, Schauer G, et al. Quitting smoking among adults - United States, 2000-2015. 2017. 1545-861X (Electronic) 0149-2195. Accessed Jan 6, 2021. https://www.ncbi.nlm.nih.gov/ pubmed/28056007. 3. Jamal A, Dube SR, Malarcher AM, et al. Tobacco use screening and counseling during physician office visits among adults--National Ambulatory Medical Care Survey and National Health Interview Survey, United States, 2005-2009. MMWR Suppl. 2012;61:38–45. 4. Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013;2013:CD000165. 5. Lindson N, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019;4:CD013308. 6. Suissa K, Lariviere J, Eisenberg MJ, et al. Efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes. 2017;10:e002458. 7. Hartmann-Boyce J, Livingstone-Banks J, Ordonez-Mena JM, et al. Behavioural interventions for smoking cessation: an overview and network metaanalysis. Cochrane Database Syst Rev. 2021;1:CD013229. 8. Skotsimara G, Antonopoulos AS, Oikonomou E, et al. Cardiovascular effects of electronic cigarettes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2019;26:1219–1228. 9. Hartmann-Boyce J, McRobbie H, Lindson N, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2021;4:CD010216. 10. Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019;380:629–637. 11. He J, Vupputuri S, Allen K, et al. Passive smoking and the risk of coronary heart disease-a meta-analysis of epidemiologic studies. N Engl J Med. 1999;340:920–926. 12. Panagiotakos DB, Pitsavos C, Stefanadis C. Chronic exposure to second hand smoke and 30-day prognosis of patients hospitalised with acute coronary syndromes: the Greek study of acute coronary syndromes. Heart. 2007;93:309–312. 13. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596–e646. 14. Duncan MS, Freiberg MS, Greevy RA Jr., et al. Association of smoking cessation with subsequent risk of cardiovascular disease. JAMA. 2019;322:642–650. 15. Ding N, Sang Y, Chen J, et al. Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases. J Am Coll Cardiol. 2019;74:498–507. 16. Franck C, Filion KB, Eisenberg MJ. Smoking cessation in patients with acute coronary syndrome. Am J Cardiol. 2018;121:1105–1111. 17. Willett J, Achenbach S, Pinto FJ, et al. The tobacco endgame: eradicating a worsening epidemic: a joint opinion from the American Heart Association, Downloaded from http://ahajournals.org by on October 7, 2026